Scalper1 News
British biotech Adaptimmune Therapeutics (ADAP) fattened its IPO and priced at the high end of its range late Tuesday, but that seemed to be more than enough for investors as the stock dropped 5.9% to close at 16 in its debut Wednesday. Adaptimmune priced 11.3 million shares, up from the previously announced 9.4 million, at 17 apiece. The company is the latest new issue developing cancer therapy using T cells, though it’s using a different Scalper1 News
Scalper1 News